#1 Clinical Trials Search in Europe

Fenfluramine Hydrochloride

Fenfluramine hydrochloride, also known as ZX008 or Fintepla, is emerging as a potential treatment for rare and severe forms of epilepsy, particularly in children and young adults. This article explores the ongoing clinical trials investigating the efficacy and safety of fenfluramine hydrochloride in conditions such as Dravet syndrome, Lennox-Gastaut syndrome, and other epileptic encephalopathies. These studies aim to provide new hope for patients with difficult-to-treat seizure disorders.

Table of Contents

What is Fenfluramine Hydrochloride?

Fenfluramine hydrochloride is a medication being studied for the treatment of rare epilepsy disorders. It is also known by the brand name Fintepla and the research code ZX008[1]. Fenfluramine comes as a clear, cherry-flavored oral solution[2].

What Conditions Does Fenfluramine Treat?

Fenfluramine is primarily being studied to treat the following rare epilepsy conditions:

  • Dravet syndrome: A severe form of epilepsy that begins in infancy and causes frequent, prolonged seizures[2]
  • Lennox-Gastaut syndrome: Another severe form of epilepsy that causes multiple types of seizures and intellectual disability[3]
  • Sunflower syndrome: A rare epilepsy disorder characterized by seizures triggered by bright light[4]
  • Infantile spasms: A type of seizure that occurs in young children[5]

How Does Fenfluramine Work?

Fenfluramine works in two main ways to help control seizures:

  1. It stimulates the release of serotonin in the brain. Serotonin is a neurotransmitter (brain chemical) that can help reduce seizure activity.
  2. It activates sigma-1 receptors in the brain, which may also help prevent seizures[1].

This unique mechanism of action makes fenfluramine different from many other anti-seizure medications.

How is Fenfluramine Administered?

Fenfluramine is given as an oral solution (liquid medicine taken by mouth). The dose is usually divided into two daily doses, taken in the morning and evening[4]. The exact dose depends on factors like:

  • The patient’s weight
  • The specific condition being treated
  • Other medications the patient is taking

For example, in some studies, the maximum dose was 0.7 mg/kg/day up to 26 mg/day. For patients also taking a medication called stiripentol, the maximum dose was lower – 0.4 mg/kg/day up to 17 mg/day[2].

How Effective is Fenfluramine?

Early research shows promising results for fenfluramine in treating rare epilepsies:

  • In one study of patients with Dravet syndrome, fenfluramine reduced convulsive seizures by 74.9% compared to 19.2% in the placebo group. Additionally, 16% of children treated with fenfluramine became seizure-free[2].
  • For Sunflower syndrome, the goal is to reduce seizures by 30% or more[4].
  • Studies are also looking at improvements in cognitive function, behavior, and quality of life for patients taking fenfluramine[3].

Safety and Side Effects

As with any medication, fenfluramine can cause side effects. Researchers are carefully monitoring patients for:

  • Changes in heart function, including heart valve problems
  • Changes in blood pressure and heart rate
  • Effects on growth (height and weight)
  • Changes in mood or behavior
  • Other potential side effects[3]

Long-term safety studies are ongoing to better understand the risks and benefits of fenfluramine[3].

Ongoing Research

Several clinical trials are currently studying fenfluramine for various purposes:

  • Testing its use in very young children (under 2 years old) with Dravet syndrome[2]
  • Evaluating its long-term safety and effectiveness[3]
  • Investigating its potential effects on cognitive function in healthy volunteers[1]
  • Studying its use in adult patients with Dravet syndrome[6]

These ongoing studies will help researchers better understand how fenfluramine can be used safely and effectively to treat rare epilepsy disorders.

Aspect Details
Drug Name Fenfluramine Hydrochloride (ZX008, Fintepla)
Primary Conditions Studied Dravet syndrome, Lennox-Gastaut syndrome, Epileptic encephalopathies
Administration Oral solution, typically twice daily
Dosage Range 0.2 mg/kg/day to 0.8 mg/kg/day, maximum 30 mg/day (lower when combined with stiripentol)
Primary Outcome Measures Reduction in seizure frequency, safety and tolerability
Secondary Outcome Measures Quality of life, cognitive function, behavior, EEG patterns
Safety Monitoring Echocardiograms, body weight, neurological exams, laboratory tests
Age Groups Studied Varies by trial; includes children, adolescents, and adults
Study Designs Open-label, randomized controlled trials, expanded access programs
Treatment Duration Ranges from 12 weeks to 36 months in different trials

FAQ

  • What is fenfluramine hydrochloride used to treat? Fenfluramine hydrochloride is being studied as a treatment for rare epilepsy syndromes, including Dravet syndrome, Lennox-Gastaut syndrome, and other epileptic encephalopathies. It has shown promise in reducing seizure frequency in patients who have not responded well to other medications.
  • How is fenfluramine hydrochloride administered? Fenfluramine hydrochloride is typically administered as an oral solution, with doses adjusted based on the patient's weight and specific condition. It is usually given twice daily, in the morning and evening.
  • What are the main goals of the clinical trials studying fenfluramine hydrochloride? The main goals of these trials are to evaluate the efficacy of fenfluramine in reducing seizure frequency, assess its long-term safety and tolerability, and determine its effects on quality of life, cognitive function, and behavior in patients with rare epilepsy syndromes.
  • Are there any potential side effects of fenfluramine hydrochloride? While the full safety profile is still being studied, some potential side effects being monitored include changes in heart function, effects on body weight, and possible impacts on cognitive and behavioral measures. Regular monitoring through echocardiograms and other tests is typically part of the treatment protocol.
  • Who is eligible to participate in these clinical trials? Eligibility varies by study, but generally includes patients with specific rare epilepsy syndromes who have not responded adequately to other treatments. Age ranges differ between trials, with some focusing on children and young adults, while others include adult patients as well.

Ongoing Clinical Trials on Fenfluramine Hydrochloride

  • Long-Term Safety Study of Fenfluramine for Patients with Myoclonic Astatic Epilepsy (Doose Syndrome)

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • A Phase 3 Study of Fenfluramine Hydrochloride for Safety and Efficacy in Patients with Rett Syndrome

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +1

  • Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany Ireland Italy The Netherlands +2

  • Long-Term Safety Study of Fenfluramine Hydrochloride for Seizures in Patients with Dravet or Lennox-Gastaut Syndrome

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Poland Spain

  • Study on the Safety and Effects of Fenfluramine in Infants Aged 1 to Less Than 2 Years with Dravet Syndrome

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Germany Italy Spain

Glossary

  • Dravet syndrome: A rare, severe form of epilepsy that begins in infancy and is characterized by frequent, prolonged seizures and developmental delays.
  • Lennox-Gastaut syndrome: A severe form of epilepsy that usually begins in childhood and is characterized by multiple types of seizures and intellectual disability.
  • Epileptic encephalopathy: A group of severe epilepsy syndromes where the epileptic activity itself contributes to severe cognitive and behavioral impairments.
  • Fenfluramine hydrochloride: An investigational drug being studied for its potential to reduce seizures in rare epilepsy syndromes. It works by modulating serotonin levels in the brain.
  • Convulsive seizure: A type of seizure involving violent muscle contractions and loss of consciousness.
  • Echocardiogram: A test that uses sound waves to create images of the heart, used to monitor heart function in patients taking fenfluramine.
  • Clinical Global Impression (CGI): A scale used by healthcare providers to assess the overall improvement or worsening of a patient's condition during treatment.
  • Quality of Life in Childhood Epilepsy (QOLCE): A questionnaire used to assess how epilepsy affects a child's day-to-day functioning in various life areas.
  • Electroencephalogram (EEG): A test that records electrical activity in the brain, often used to diagnose and monitor epilepsy.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT05026398
  2. https://clinicaltrials.gov/study/NCT06598449
  3. https://clinicaltrials.eu/trial/long-term-safety-study-of-fenfluramine-hydrochloride-for-seizures-in-patients-with-dravet-or-lennox-gastaut-syndrome/
  4. https://clinicaltrials.gov/study/NCT03790137
  5. https://clinicaltrials.gov/study/NCT04289467
  6. https://clinicaltrials.gov/study/NCT05560282